REM23 Antibody
Description
Clarification of Nomenclature and Potential Misidentifications
The term "REM23" may derive from:
-
Gene/Protein Context: REM1 (RRAD and GEM-like GTPase 1), a small GTPase involved in cellular signaling .
-
Antibody Targets: IL-23 (interleukin-23), a cytokine implicated in autoimmune diseases. For example, ABT-874 targets IL-12/23 .
-
Typographical Errors: Possible confusion with "REGEN-COV" (REGN10933 + REGN10987), a SARS-CoV-2-targeting antibody cocktail .
No antibody explicitly named "REM23" is listed in:
IL-12/23-Targeting Antibodies
ABT-874 (anti-IL-12/23) was investigated for multiple sclerosis (MS):
SARS-CoV-2 Neutralizing Antibodies
REGEN-COV (casirivimab + imdevimab) demonstrated resistance to viral escape:
Bispecific Antibodies in Oncology
Ivonescimab (SMT112), a PD-1/VEGF bispecific antibody, is in Phase 3 trials for NSCLC:
Antibody-Based Diagnostics
Monoclonal antibodies enable precise detection of biomarkers:
| Use Case | Example Antibody | Application |
|---|---|---|
| Pregnancy Testing | Anti-hCG | Detects hCG in urine/serum . |
| Cancer Imaging | Radio-labeled anti-tumor antibodies | Identifies cancerous cells via radioisotopes . |
Preclinical Remyelination Studies
Mouse natural IgMs (e.g., rHIgM22) promote remyelination in CNS demyelinating diseases:
Emerging Trends in Antibody Engineering
-
Non-Competing Combinations: REGEN-COV’s dual antibodies bind distinct RBD epitopes, preventing viral escape .
-
Fc Engineering: Modifications (e.g., L234A, L235A) reduce effector functions, enhancing safety .
-
Bispecific Formats: Tetravalent designs (e.g., ivonescimab) enable simultaneous targeting of two pathways .
Product Specs
Constituents: 50% Glycerol, 0.01M Phosphate Buffered Saline (PBS), pH 7.4
